

BIOGEN IDEC INC.  
Form 8-K  
June 14, 2013

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 12, 2013

Biogen Idec Inc.

(Exact name of registrant as specified in its charter)

Delaware

0-19311

33-0112644

(State or other jurisdiction of incorporation) (Commission File Number)

(IRS Employer Identification No.)

133 Boston Post Road, Weston, Massachusetts 02493

(Address of principal executive offices; Zip Code)

Registrant's telephone number, including area code: (781) 464-2000

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

.. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

.. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

.. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

.. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Item 5.07 Submission of Matters to a Vote of Security Holders

On June 12, 2013, Biogen Idec Inc. (the "Company") held its Annual Meeting of Stockholders. The final voting results for this meeting are as follows:

Stockholders elected twelve nominees to the Board of Directors to serve for a one-year term extending until the 1.2014 annual meeting of stockholders and their successors are duly elected and qualified, with the votes cast as follows:

| Nominee              | Votes For   | Votes<br>Against | Abstentions | Broker<br>Non-Votes |
|----------------------|-------------|------------------|-------------|---------------------|
| Alexander J. Denner  | 200,671,488 | 577,986          | 218,852     | 14,344,114          |
| Caroline D. Dorsa    | 201,034,820 | 219,129          | 214,377     | 14,344,114          |
| Nancy L. Leaming     | 201,021,123 | 228,459          | 218,744     | 14,344,114          |
| Richard C. Mulligan  | 200,014,037 | 1,235,729        | 218,560     | 14,344,114          |
| Robert W. Pangia     | 199,358,134 | 1,892,398        | 217,794     | 14,344,114          |
| Stelios Papadopoulos | 199,727,079 | 1,515,686        | 225,561     | 14,344,114          |
| Brian S. Posner      | 199,740,106 | 1,502,446        | 225,774     | 14,344,114          |
| Eric K. Rowinsky     | 199,926,343 | 1,322,631        | 219,352     | 14,344,114          |
| George A. Scangos    | 200,988,795 | 257,446          | 222,085     | 14,344,114          |
| Lynn Schenk          | 199,312,537 | 1,937,372        | 218,417     | 14,344,114          |
| Stephen A. Sherwin   | 179,235,245 | 22,011,561       | 221,520     | 14,344,114          |
| William D. Young     | 199,620,623 | 1,584,136        | 263,567     | 14,344,114          |

Stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company's independent registered public 2. accounting firm for the fiscal year ending December 31, 2013, with the votes cast as follows: 212,343,173 votes for; 3,233,008 votes against; 236,259 abstentions; 0 broker non-votes.

Stockholders approved the advisory vote on executive compensation, with the votes cast as follows: 197,974,068 3. votes for; 3,027,018 votes against; 466,862 abstentions; 14,344,492 broker non-votes.

Stockholders reapproved the material terms of the performance goals under the Biogen Idec Inc. 2008 4. Performance-Based Management Incentive Plan for purposes of Section 162(m) of the Internal Revenue Code, with the votes cast as follows: 197,033,424 votes for; 4,120,424 votes against; 314,100 abstentions; 14,344,492 broker non-votes.

Stockholders reapproved the material terms of the performance goals under the Biogen Idec Inc. 2008 Omnibus 5. Equity Plan for purposes of Section 162(m) of the Internal Revenue Code, with the votes cast as follows: 196,445,916 votes for; 4,704,986 votes against; 317,046 abstentions; 14,344,492 broker non-votes.

Stockholders did not approve the stockholder proposal regarding adoption of a share retention policy, with the votes 6. cast as follows: 41,204,998 votes for; 159,692,409 votes against; 570,541 abstentions; 14,344,492 broker non-votes.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOGEN IDEC INC.

By: /s/ Robert A. Licht  
Robert A. Licht  
Senior Vice President

Date: June 14, 2013